Drugs / Nebilet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00942487 | Apr 2005 → Dec 2008 | essential hypertension | Berlin-Chemie Menarini | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nebilet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00942487 ↗ |
| Known as | nebivolol | “Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration” NCT00942487 ↗ |
| Route | Oral | “for oral administration” NCT00942487 ↗ |